Methicillin resistance among Trinidadian isolates of community and hospital strains of Staphylococcus aureus and their patterns of resistance to non-beta-lactam antibiotics

The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) strains in Trinidad and the extent of their resistance to other antimicrobial agents in hospital-acquired infections were evaluated over a 2-year period. A total of 450 S. aureus strains were isolated from different patients. The prevalence of methicillin resistance among S. aureus strains was 9.8 percent (44/450). The proportion of MRSA isolated from hospital sources and community sources was 12.5 percent (38/305) and 4.1 percent (6/145) respectively (P<0.05). The resistant rates of MRSA to the non-beta-lactam antibodies were as follows: 93.2 percent resistance to tetracycline, 68.2 percent to erythromycin, 61.4 percent to gentamicin, 45.5 percent to co-trimoxazole, and 20.5 percent to ciprofloxacin. No MRSA resistant to vancomycin was observed in this study. Study results showed significant increases in MRSA in hospital, 2 percent in 1995 to 12.5 percent in 1998 (P<0.05), and community, 0 percent in 1995 to 4.1 percent in 1998 (P<0.05). It has become apparent that infection must be focussed now on the community in order to monitor and limit the spread of this new and expanding reservoir of MRSA. (AU)

Methicillin resistance among Trinidadian isolates of community and hospital strains of Staphylococcus aureus and their patterns of resistance to non-beta-lactam antibiotics

The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) strains in Trinidad and the extent of their resistance to other antimicrobial agents in hospital-acquired and community-acquired infections were evaluated over a 2-year period. A total of 450 S. aureus strains were isolated from different patients. The prevalence of methicillin resistance among S. aureus strains was 9.8% (44/450). The proportion of MRSA isolated from hospital sources and community sources was 12.5% (38/305) and 4.1% (6/145), respectively (P < 0.05). The resistant rates of MRSA to the non-beta-lactam antibiotics were as follows: 93.2% resistance to tetracycline, 68.2% to erythromycin, 61.4% to gentamicin, 45.5% to co-trimoxazole, and 20.5% to ciprofloxacin. No MRSA resistant to vancomycin was observed in this study. Study results showed significant increases in MRSA in hospital, 2% in 1995 to 12.5% in 1998 (P < 0.05), and community, 0% in 1995 to 4.1% in 1998 (P < 0.05). It has become apparent that infection control and surveillance initiatives must be focused now on the community in order to monitor and limit the spread of this new and expanding reservoir of MRSA.

Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin

The purpose of this study was to determine the role of enteroaggregative Escherichia coli (EAEC) in the development of traveler's diarrhea and the clinical response of patients with EAEC diarrhea following treatment with ciprofloxacin. Sixty-four travelers with diarrhea and no other recognized enteropathogen were enrolled in treatment studies in Jamaica and Mexico from July 1997 to July 1998. EAEC was isolated from 29 travelers (45.3 percent). There was a significant reduction in the duration of posttreatment diarrhea in the 16 patients treated with ciprofloxacin, as compared with that in the 13 patients who received placebo (mean of 35.3 versus 55.5 hours; P= .049). There was a nonsignificant reduction in the mean number of unformed stools passed during the 72 hours after enrollment in the ciprofloxacin-treated group (7.5) (P= .128). This study provides additional evidence that EAEC should be considered as a cause of antibiotic-responsive traveler's diarrhea. (AU)

Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea

Diarrhoea is the most common illness affecting travellers to developing countries. Our study was designed to compare the efficacy of a single 500 mg dose of ciprofloxacin with placebo for treatment of acute diarrhoea in travellers. British troops who were within their first 8 weeks of deployment in Belize and who presented within 24h of the onset of diarrhoea, were randomised to receive either ciprofloxacin 500 mg or placebo. Every subject recorded the number and consistency of stools and presence of any other associated symptoms for 72 h or until recovery. Of 88 subjects enrolled, 83 were evaluable, of whom 45 received ciprofloxacin and 38 placebo. Groups did not differ with regard to duration or severity of diarrhoea at randomisation. Mean (SE) duration of diarrhoea, as assessed by time to the last liquid and last unformed stool, was reduced from 50.4 (4.5) h and 53.5 (4.4) h, respectively, in the placebo group to 20.9 (3.4) h and 24.8 (3.8) h in those receiving ciprofloxacin (p<0.0001). Mean number of liquid stools was reduced from 11.4 (1.2) in the placebo group to 5.0 (0.7) in the ciprofloxacin-treated group (p<0.0001). The cumulative percentages of subjects with no unformed stool after 24 h, 48 h, and 72 h were, respectively, 64 percent, 82 percent, and 93 percent in the ciprofloxacin group and 11 percent, 42 percent, and 79 percent in the placebo group (p<0.0001, p<0.001, and not significant, respectively). A single 500 mg dose of ciprofloxacin was an effective empirical treatment for reducing the duration and severity of diarrhoea in travellers. The regimen should maximise compliance and reduce the cost and duration of therapy (AU)